Loading
A phase 1/2 trial of AK117, Carboplatin, Cisplatin and Gemcitabine in advanced solid tumours, run by Akeso, active and no longer recruiting.
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05229497 by Akeso, with 154 participants enrolled, started 2022-05-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil and Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Akeso, Gemcitabine, Cisplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/